News

The U.S. Food and Drug Administration (FDA) has lifted its clinical hold on deucrictibant as a prophylactic, or preventive, treatment for hereditary angioedema (HAE) attacks. Deucrictibant developer Pharvaris said it will resume clinical testing of the therapy in HAE, including restarting the open-label extension part of the…

The investigational therapy donidalorsen was well tolerated and significantly reduced the rate of swelling attacks in hereditary angioedema (HAE) patients, meeting the main goal of the Phase 3 OASIS-HAE trial. Other secondary trial goals were also met, according to Ionis Pharmaceuticals, which is developing the treatment. The company…

Long-term preventive treatment with Haegarda reduced the number and severity of attacks and the use of rescue medications in people with hereditary angioedema (HAE), while improving their quality of life, a recent study has found. “These real-world findings indicate that long-term prophylaxis with [Haegarda] markedly improves important factors that…

In a 39-year-old man in France, hereditary angioedema (HAE) manifested with stroke-like symptoms, including weakness on one side of the body and difficulty speaking, despite treatment with danazol, a medication normally used to prevent HAE attacks. His symptoms eventually resolved with Takhzyro (lanadelumab), an approved therapy for…

Long-term use of attenuated androgens — male hormones used as a preventive treatment — may increase the risk for other disorders in hereditary angioedema with C1 inhibitor deficiency (C1-INH-HAE), a retrospective analysis suggests. Disorders linked with their use included high blood pressure, high cholesterol, diabetes, and benign liver tumors. “The results…

With Phase 3 clinical trial results on Ionis Pharmaceuticals’ donidalorsen for hereditary angioedema (HAE) due by mid-year, the company has struck a deal with Otsuka Pharmaceutical for the  commercialization of the preventive treatment in Europe. “We are excited to collaborate with Otsuka given their proven results in bringing…

Throughout 2023, we at Angioedema News have been bringing you coverage of the latest news related to angioedema, from basic research to clinical trials and advances in treatment. Here we’ve compiled a list of the top 10 most-read articles we’ve published this past year. We look forward to…

Preventive treatment with Orladeyo (berotralstat) was associated with improved treatment satisfaction among hereditary angioedema (HAE) patients who had switched from injectable therapies, according to a recent clinical trial analysis. BioCryst Pharmaceutical’s oral treatment also was well tolerated and associated with low HAE attack rates, as has been…

People with hereditary angioedema (HAE) who switched from long-term androgen treatment to BioCryst Pharmaceuticals’ Orladeyo (berotralstat) saw a reduction in the number of swelling attacks. That’s according to a new analysis of data from patients who discontinued androgens less than 60 days (two months) before entering APeX-S…

Long-term prophylaxis, or preventive treatment, with Orladeyo (berotralstat) is well tolerated, and results in sustained reductions in swelling attacks and gains in quality of life in adolescents and adults with hereditary angioedema (HAE). That’s according to nearly two years of data from the completed Phase 3 APeX-2…